Superior Weight Loss: Clinical trials (e.g., AM833 studies) show the combination can achieve ~17-25% body weight reduction, surpassing semaglutide alone.
Better Glycemic Control: Enhanced glucose-lowering effects, beneficial for type 2 diabetes or prediabetes.
Tolerability: Gradual dose escalation minimizes side effects like nausea, common with GLP-1 agonists.
Potential Broader Impact: May improve obesity-related comorbidities (e.g., hypertension, dyslipidemia) more effectively than monotherapy.